<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/41A6F529-3374-4F2A-8350-29C571A8C235"><gtr:id>41A6F529-3374-4F2A-8350-29C571A8C235</gtr:id><gtr:name>European Commission (EC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/961756BF-E31F-4A13-836F-0A09BA02385C"><gtr:id>961756BF-E31F-4A13-836F-0A09BA02385C</gtr:id><gtr:name>University of Exeter</gtr:name><gtr:department>Institute of Biomed &amp; Clinical Science</gtr:department><gtr:address><gtr:line1>University of Exeter</gtr:line1><gtr:line2>Clydesdale House</gtr:line2><gtr:line3>Clydesdale Road</gtr:line3><gtr:line4>Exeter</gtr:line4><gtr:postCode>EX4 4QX</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/961756BF-E31F-4A13-836F-0A09BA02385C"><gtr:id>961756BF-E31F-4A13-836F-0A09BA02385C</gtr:id><gtr:name>University of Exeter</gtr:name><gtr:address><gtr:line1>University of Exeter</gtr:line1><gtr:line2>Clydesdale House</gtr:line2><gtr:line3>Clydesdale Road</gtr:line3><gtr:line4>Exeter</gtr:line4><gtr:postCode>EX4 4QX</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/41A6F529-3374-4F2A-8350-29C571A8C235"><gtr:id>41A6F529-3374-4F2A-8350-29C571A8C235</gtr:id><gtr:name>European Commission (EC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E85CC15B-5865-4815-84A9-CBD70BCB93E8"><gtr:id>E85CC15B-5865-4815-84A9-CBD70BCB93E8</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Randall</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1F83CAE9-71ED-414E-A7EE-047B09640CBE"><gtr:id>1F83CAE9-71ED-414E-A7EE-047B09640CBE</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>Thomas</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100623"><gtr:id>8EED869E-4543-49E1-A110-31F8CCE5DA5A</gtr:id><gtr:title>Modified intrinsic excitability in transgenic mouse models of progressive beta-amyloidopathy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100623</gtr:grantReference><gtr:abstractText>Alzheimer?s disease (AD) is devastating and frightening for both sufferers and their families. In its early stages, Alzheimer?s leads to memory loss and confusion; at its peak, it leads to a complete breakdown of mental ability as brain tissue degenerates and the electrical activity underlying brain function breaks down. We are living to ever greater ages and therefore are more likely to fall victim to AD. Research into what goes wrong with the brain in AD is therefore increasingly important. We can recreate some of the conditions that occur in the AD patient?s brain by genetically modifying mice. For example, we can produce mice that accumulate the toxic peptide beta-amyloid in their brain as they age. High levels of these peptides are a key feature of AD and are thought by most researchers to be key causative factor. Information in the brain is largely encoded by brief electrical signals (spikes) generated when individual nerve cells (neurones) become stimulated. These neurones are connected together in large networks, and it is these neuronal networks which are thought to process and store memories. Disturbances in such neuronal networks are thought to underlie many disorders of memory, including those in AD. We have recently been trying to understand the causes of these electrical disturbances in AD by studying mouse models that overproduce beta-amyloid. To do this we record the electrical activity of individual neurones in the hippocampus, an area of the brain crucial for memory. This recently allowed us to identifying striking changes to the shape, size and patterns of spikes in mouse models of AD. These changes result from a reduced flow of sodium ions across the cell membrane via specialised proteins called sodium channels. We believe that if such changes are paralleled in man they will contribute substantially to the cognitive deficits that are a hallmark of AD. Using AD model mice we propose to further investigate the relationship between the changes to electrical properties of the brain and the age-dependent over-production of beta-amyloid. This will allow us to compare our findings with other studies of disease progression in these mice We will also investigate how the changes to sodium channels and spikes are produced and will also use secretase inhibitor drugs, similar to those in clinical trails, to attempt to reverse the alterations to electrical activity that develop as our mice age.</gtr:abstractText><gtr:technicalSummary>Alzheimer?s disease (AD) is the major cause of dementia in the elderly. Our laboratory is interested in characterising neurophysiological deficits that arise in AD and understanding their causal mechanisms. To do this we apply a variety of electrophysiological methods to study of pre-clinical animal models of AD-related pathology. Much of our work employs transgenic mice which over-produce Abeta peptides, molecules that are widely believed to play a crucial role in the pathophysiology of AD. In recent years, work with such mice, by ourselves and others has begun to reveal significant disturbances to synchronous network activity in the cortex and hippocampus, brain structures with crucial roles in cognitive function. In vivo EEG recordings reveal network hyperexcitability in these areas, which in some laboratories resembles epileptic activity. It is proposed that these disturbed patterns of network activity are likely to contribute to cognitive dysfunction in AD. As well as performing our own in vivo recordings, we have been investigating cellular level neurophysiological factors that could be the cause of these disturbed patterns of neuronal activity. Our work has focussed on modifications to intrinsic neuronal excitability, an aspect of neurophysiology well known to contribute to network hyperfunction in epilepsy. Using patch clamp recording from CA1 pyramidal cells in hippocampal slices, we have identified robust changes to intrinsic neuronal excitability and action potential waveforms in 2 different Abeta overproducing mouse lines. We also used nucleated macropatch recordings to identify a ~50% loss of voltage-gated sodium currents from the cell bodies of these neurones; potassium currents were, in contrast, entirely unaltered. All of these changes were absent in young animals, and their presence seems to parallel Abeta burden since they arise earlier in the more aggressive PSAPP double transgenic line. This application requests funding to follow up these findings in much greater detail. Our goals include: 1) Generating a more detailed understanding of the timecourse with which both altered excitability and sodium current depression arise. 2) Determining if similar changes to those observed in pyramidal cells occur in GABAergic interneurones. 3) Establishing if the changes to either excitability and/or Na+ channels can be reversed by pharmacological interventions that reduce CNS amyloid load. 4) Using dynamic clamp to establish if altered sodium current levels are solely responsible for the altered intrinsic excitability. 5) Examining if related changes to excitability and ion channels levels are seen in the axonal or dendritic compartments.</gtr:technicalSummary><gtr:fund><gtr:end>2016-04-26</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>784140</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>New studentship partnership with Eli Lilly</gtr:description><gtr:id>A610BFFD-F660-480B-A5C9-07F1EDFE54A6</gtr:id><gtr:impact>We have taken on 2 good new students who started in September 2013.</gtr:impact><gtr:partnerContribution>Financial input to partially support 2 students</gtr:partnerContribution><gtr:piContribution>Based on ongoing work in this project we received funding from Eli Lilly to support two new studentships doing related experiments in other aspsects of Alzheimer's disease biology</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission (EC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>Membership of Pharmacog IMI</gtr:description><gtr:id>442781FC-3364-455C-B1DC-4C9F2674363F</gtr:id><gtr:impact>We have received some cohorts of experimental animals. I also did some media work relating to our inclusion (e.g. BBC radio Bristol)</gtr:impact><gtr:partnerContribution>We have shared our original datasets from the first few months of the grant.</gtr:partnerContribution><gtr:piContribution>Following on from the award of our MRC grant we were co-opted into the established EU funded Pharmacog IMI. This large consortium of academic and private sector Alzheimer's Disease researchers now provide our animals for the MRC grant (they were formally due to come from Pfizer).</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>New studentship support from AstraZeneca</gtr:description><gtr:id>0A6F2BA0-B8A4-404B-B227-2C07024D82BA</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:partnerContribution>Funding to extend a studentship from 3 to 4 years and to provide consumables</gtr:partnerContribution><gtr:piContribution>New funding to support a PhD student based on work carried out under existing grant</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>New CASE award</gtr:description><gtr:id>75E2724D-6871-41D3-971D-BD528D9E2721</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:partnerContribution>Funding and iPSC lines made by some of their other collaborators</gtr:partnerContribution><gtr:piContribution>Based on worked performed by MRC funded post-doc we were able to propose this new award</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>CASE studentship from AstraZeneca</gtr:description><gtr:id>53F3B98C-ACD3-404C-9161-BECFCC2E06EB</gtr:id><gtr:impact>This is yet to start but results from current award</gtr:impact><gtr:partnerContribution>Standard CASE award contributions plus additional consumable costs</gtr:partnerContribution><gtr:piContribution>Based on work to date we will start a new PhD studentship with AZ in 2015</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visit by major research donors to see lab in action</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC0156ED-8868-4575-B416-02FED915D81A</gtr:id><gtr:impact>We gave a presentation about dementia research at Exeter and then hosted visitors in laboratory showing live brain slice recording from model mice supported by this award

Visit resulted in additional donation to the University for dementia research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of science Exeter</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B129F528-4A74-4D78-972B-D15BA9843EF2</gtr:id><gtr:impact>Dementia Talk at Pint of Science Exeter</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement via Bristol Neuroscience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>579B060E-75B4-4E47-8236-B7BB194F22C5</gtr:id><gtr:impact>Large numbers of the public visited the Bristol Neuroscience booth to learn about our research and that of Bristol colleagues

not know</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview (LBC)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C63BA2B4-C9FC-4007-8887-3369E6DCF639</gtr:id><gtr:impact>Interview on LBC Saturday night programme about a news story in age related cognitive decline

none</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hosting of 6th form scientists for experimental work placement</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CA01A856-9ACA-41E8-A893-2EBBF246E5D6</gtr:id><gtr:impact>School age scientists worked in laboratory with PI doing &amp;quot;real&amp;quot; experimental work

Greater knowledge about neuroscience - and resultant UCAS applications in this subject</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>newspaper contributions (Daily Mail, Guardian, Telegraph)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>64262BFE-94AA-47B3-BEA5-2A883B3B32ED</gtr:id><gtr:impact>Published comments on work by a group at Stanford following approach to Bristol press office.

Have become increasingly a talking head on issue of aging related cognitive dysfunction</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8BA97EE8-EBFF-4C6D-B45F-CA3ECEF5C3FA</gtr:id><gtr:impact>Pint of Science presentation in Bristol on the subject of dementia</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview (BBC Radio Bristol)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8DC73811-9163-4C83-89F5-D7C30CF22595</gtr:id><gtr:impact>Talking about Alzheimer's disease on BBC radio Bristol

Invited back for more appearances</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fellowship</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>F7D7986A-C9F8-4AD7-9315-97676154FB73</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alzheimer's Research UK Network Collaboration</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>9ECDFFDF-C463-47CD-8AED-487BCC0339F6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>820000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral training centre</gtr:description><gtr:end>2020-04-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>F9B39602-4607-4977-A2C9-2EF60147025B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK equipment grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>1BE9E4CD-93AA-47D1-A330-C35857903B91</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>641000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre; Wellcome Trust</gtr:department><gtr:description>Multiuser equipment award</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>88AF81FD-8AE5-4A8A-AC67-94E3E7BC5C8E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>68000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Co-funded studentship</gtr:description><gtr:end>2021-02-02</gtr:end><gtr:fundingOrg>Janssen Research &amp; Development</gtr:fundingOrg><gtr:id>6860A8D5-9DF5-41C2-87DA-480BBCFDF884</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3Rs CRACK</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>D8143F64-E40B-4EC8-A2CE-8C481D6DEFBD</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK fellowship</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>200616AC-571A-46E9-9F07-689F8A2397AB</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Models of hippocampal neurons impacted by disease states</gtr:description><gtr:id>0EB9F47A-C79B-4300-90F0-77C7C9E7E3CF</gtr:id><gtr:impact>Nothing as yet but it is early days</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>neuronal models</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of 3D cultures of human iPSC cells with novel hydrogels that promote neuronal maturation</gtr:description><gtr:id>4E6AE2E8-33F9-477D-9E41-656C177679C8</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>3D hydrogel cultures</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/221152D4-D911-405F-B720-08C03F17922D"><gtr:id>221152D4-D911-405F-B720-08C03F17922D</gtr:id><gtr:title>A new player in the &amp;quot;synaptopathy&amp;quot; of Alzheimer's disease - arc/arg 3.1.</gtr:title><gtr:parentPublicationTitle>Frontiers in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af58cd093969ffce9dc103a503a05b86"><gtr:id>af58cd093969ffce9dc103a503a05b86</gtr:id><gtr:otherNames>Kerrigan TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-2295</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D4C1DC1-33EA-4BCE-855D-A582E62E8F8C"><gtr:id>9D4C1DC1-33EA-4BCE-855D-A582E62E8F8C</gtr:id><gtr:title>Electrical and Network Neuronal Properties Are Preferentially Disrupted in Dorsal, But Not Ventral, Medial Entorhinal Cortex in a Mouse Model of Tauopathy.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f9d4266317452a3ce7e2167ee3f4594"><gtr:id>6f9d4266317452a3ce7e2167ee3f4594</gtr:id><gtr:otherNames>Booth CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA0E2D6C-5CCA-4C5A-8B17-7B018856CE22"><gtr:id>CA0E2D6C-5CCA-4C5A-8B17-7B018856CE22</gtr:id><gtr:title>Intrinsic excitability changes induced by acute treatment of hippocampal CA1 pyramidal neurons with exogenous amyloid ? peptide.</gtr:title><gtr:parentPublicationTitle>Hippocampus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7fe8e73625512797cb0ab8998b4ee89"><gtr:id>e7fe8e73625512797cb0ab8998b4ee89</gtr:id><gtr:otherNames>Tamagnini F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1050-9631</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C06583A-9E17-4BEF-8FF8-D342F76074DD"><gtr:id>3C06583A-9E17-4BEF-8FF8-D342F76074DD</gtr:id><gtr:title>Functionalized a-Helical Peptide Hydrogels for Neural Tissue Engineering.</gtr:title><gtr:parentPublicationTitle>ACS biomaterials science &amp; engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d4f294aca8c4b19b7b72508dcf908628"><gtr:id>d4f294aca8c4b19b7b72508dcf908628</gtr:id><gtr:otherNames>Mehrban N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2373-9878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BE6F295-956C-4D8A-ABF7-5BEB29E8560E"><gtr:id>2BE6F295-956C-4D8A-ABF7-5BEB29E8560E</gtr:id><gtr:title>Whole-cell patch-clamp recording of voltage-sensitive Ca&amp;sup2;? channel currents in single cells: heterologous expression systems and neurones.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d99186fe36784093a89ae67dc4a70fcb"><gtr:id>d99186fe36784093a89ae67dc4a70fcb</gtr:id><gtr:otherNames>Brown J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89D45475-477C-4223-8AB6-F4E36F19792E"><gtr:id>89D45475-477C-4223-8AB6-F4E36F19792E</gtr:id><gtr:title>Long-term culture of pluripotent stem-cell-derived human neurons on diamond--A substrate for neurodegeneration research and therapy.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99ab071171cbb472a84f1c54c1213087"><gtr:id>99ab071171cbb472a84f1c54c1213087</gtr:id><gtr:otherNames>Nistor PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/67EBA9D9-AC13-438E-9A96-82C280C8806E"><gtr:id>67EBA9D9-AC13-438E-9A96-82C280C8806E</gtr:id><gtr:title>Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/193f80a77077793427377c1e73100ff7"><gtr:id>193f80a77077793427377c1e73100ff7</gtr:id><gtr:otherNames>Corbett BF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7ADDC013-8824-40E6-9407-B962ADBE0130"><gtr:id>7ADDC013-8824-40E6-9407-B962ADBE0130</gtr:id><gtr:title>Low concentrations of the solvent dimethyl sulphoxide alter intrinsic excitability properties of cortical and hippocampal pyramidal cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7fe8e73625512797cb0ab8998b4ee89"><gtr:id>e7fe8e73625512797cb0ab8998b4ee89</gtr:id><gtr:otherNames>Tamagnini F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B557EA9B-2D4B-4335-8237-77DA74E7F283"><gtr:id>B557EA9B-2D4B-4335-8237-77DA74E7F283</gtr:id><gtr:title>Altered intrinsic excitability of hippocampal CA1 pyramidal neurons in aged PDAPP mice.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7fe8e73625512797cb0ab8998b4ee89"><gtr:id>e7fe8e73625512797cb0ab8998b4ee89</gtr:id><gtr:otherNames>Tamagnini F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C638B7FC-9804-43B9-8EE6-C904905B478B"><gtr:id>C638B7FC-9804-43B9-8EE6-C904905B478B</gtr:id><gtr:title>Characterization of altered intrinsic excitability in hippocampal CA1 pyramidal cells of the A?-overproducing PDAPP mouse.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af58cd093969ffce9dc103a503a05b86"><gtr:id>af58cd093969ffce9dc103a503a05b86</gtr:id><gtr:otherNames>Kerrigan TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79C1EAD6-1CDB-41C6-8DDB-F6770234EF01"><gtr:id>79C1EAD6-1CDB-41C6-8DDB-F6770234EF01</gtr:id><gtr:title>Altered Intrinsic Pyramidal Neuron Properties and Pathway-Specific Synaptic Dysfunction Underlie Aberrant Hippocampal Network Function in a Mouse Model of Tauopathy.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f9d4266317452a3ce7e2167ee3f4594"><gtr:id>6f9d4266317452a3ce7e2167ee3f4594</gtr:id><gtr:otherNames>Booth CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A72B911-BC58-48B4-AC6D-5619CEBC822C"><gtr:id>0A72B911-BC58-48B4-AC6D-5619CEBC822C</gtr:id><gtr:title>Disrupted hippocampal sharp-wave ripple-associated spike dynamics in a transgenic mouse model of dementia.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dceaab03bf81d2a2232e3243611796cd"><gtr:id>dceaab03bf81d2a2232e3243611796cd</gtr:id><gtr:otherNames>Witton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100623</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>